SkinBioTherapeutics plc (AIM:SBTX)
London · Delayed Price · Currency is GBP · Price in GBX 9.56
+0.06 (0.63%)
At close: Mar 4, 2026
SkinBioTherapeutics Revenue
In the fiscal year ending June 30, 2025, SkinBioTherapeutics had annual revenue of 4.64M GBP with 283.74% growth. SkinBioTherapeutics had revenue of 3.06M in the half year ending June 30, 2025, with 5,459.30% growth.
Revenue
4.64M
Revenue Growth
+283.74%
P/S Ratio
5.34
Revenue / Employee
113.13K
Employees
41
Market Cap
24.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 4.64M | 3.43M | 283.74% |
| Jun 30, 2024 | 1.21M | 1.08M | 815.26% |
| Jun 30, 2023 | 132.06K | 57.30K | 76.64% |
| Jun 30, 2022 | 74.76K | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| hVIVO | 54.47M |
| Arecor Therapeutics | 5.06M |
| Fusion Antibodies | 1.60M |
| Aptamer Group | 1.20M |
| Ondine Biomedical | 1.18M |
| Oxford BioDynamics | 1.10M |
| ImmuPharma | -69.96K |